Modelling Marek's Disease Virus (MDV) infection: parameter estimates for mortality rate and infectiousness by Atkins, Katherine E et al.
RESEARCH ARTICLE Open Access
Modelling Marek’s Disease Virus (MDV) infection:
parameter estimates for mortality rate and
infectiousness
Katherine E Atkins
1,4*, Andrew F Read
2, Nicholas J Savill
1, Katrin G Renz
3, Stephen W Walkden-Brown
3 and
Mark EJ Woolhouse
1
Abstract
Background: Marek’s disease virus (MDV) is an economically important oncogenic herpesvirus of poultry. Since the
1960s, increasingly virulent strains have caused continued poultry industry production losses worldwide. To
understand the mechanisms of this virulence evolution and to evaluate the epidemiological consequences of
putative control strategies, it is imperative to understand how virulence is defined and how this correlates with
host mortality and infectiousness during MDV infection. We present a mathematical approach to quantify key
epidemiological parameters. Host lifespan, virus latent periods and host viral shedding rates were estimated for
unvaccinated and vaccinated birds, infected with one of three MDV strains. The strains had previously been
pathotyped to assign virulence scores according to pathogenicity of strains in hosts.
Results: Our analyses show that strains of higher virulence have a higher viral shedding rate, and more rapidly kill
hosts. Vaccination enhances host life expectancy but does not significantly reduce the shedding rate of the virus.
While the primary latent period of the virus does not vary with challenge strain nor vaccine treatment of host, the
time until the maximum viral shedding rate is increased with vaccination.
Conclusions: Our approach provides the tools necessary for a formal analysis of the evolution of virulence in MDV,
and potentially simpler and cheaper approaches to comparing the virulence of MDV strains.
Background
Marek’s Disease Virus (MDV) is an oncogenic poultry
herpesvirus of considerable economic importance to the
poultry industry. Virus strains have become increasingly
virulent since the 1960s [1,2]. The causes of this viral
evolution are unclear [3]. Quantification of patterns of
viral shedding and virus-induced host mortality are
necessary for a rigorous understanding of the epidemiol-
ogy of a disease, not least to identify increases in viru-
lence. Here we develop methods to do this.
MDV is an airborne pathogen with infection occurring
via inhalation [4]. Virus shedding occurs by infected
feather follicle epithelium [5]. The resulting dust and
dander from dead stratified cells and moulted feathers
can then remain in the environment and act as a
reservoir for chicken infection. Clinical signs are varied
and result in significant morbidity and mortality
depending on host genetic susceptibility and virulence
of the MDV strain [6]. Symptoms include polyneuritis
(an enlargement of multiple peripheral nerves), visceral
lymphoma (tumours affecting organs such as the heart,
liver, spleen etc.), acute transient paralysis, immunosup-
pression, brain oedema and acute rash. There has been
a change in the types of clinical signs since the disease
was first noted [7,8], when chronic polyneuritis was the
only sign. Since then, the list of clinical signs described
above expanded gradually over the decades [2].
Almost all industrialised countries have experienced
MD losses in their poultry industry and a crude estimate
of the cost of Marek’s disease is said to be in the range
of US $1-2 billion annually [7]. Control of Marek’s
disease is predominantly via vaccination of chickens.
Crucially the MDV vaccine was the first vaccine to be
developed against any cancer [9]. Three types of vaccine
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pesvirus of turkeys (HVT), non-pathogenic serotype 2
MDV and non-pathogenic serotype 1 [10]. These vac-
cines have been used in different sequences in different
countries and the vaccine types have also been com-
monly combined in bivalent or trivalent vaccines.
Definitions of virulence are numerous and varied [11].
Microbiologists equate virulence with the notions of
both infectivity and severity of disease, whereas evolu-
tionary biologists focus on evolutionary fitness of either
the pathogen or the host [12]. Zoologists tend to focus
on host fitness [13,14] with most mathematical models
describing this specifically as host mortality [14,15].
There have been various attempts to define virulence
in the context of MDV [16]. For example, Witter [1]
relates the percentage of HVT or Bivalent (HVT + sero-
type 2) vaccinated chickens, that when infected with a
particular strain develop gross lesions or die of Marek’s
disease within eight weeks to the figure in unvaccinated
chickens challenged with the same strain. This percen-
tage score uses the protective effect of vaccines as its
metric for virulence. In addition, [17] use neurovirulence
as a tool for pathotyping MDV strains, noting that many
of the very virulent strains are synonymous with high
levels of neuropathology. This method circumvents the
need for both vaccine-based definitions and therefore
high numbers of birds, and also may cut the experiment
time. In the first pathotyping regime, there are four
recognised MDV serotype 1 pathotypes, each occupying
part of the ‘continuum of virulence’ [1] defined as: mild,
m; virulent, v; very virulent, vv; very virulent plus, vv+.
This grouping correlates very well with the second
pathotyping regime [18].
Control strategies for MDV require an understanding
of the epidemiology of the disease, in particular how
virulence relates to key parameters such as viral shed-
ding rates and duration of infectious period. There have
been efforts to find correlates with virulence of MDV
isolates, most notably with viral load (virus within a bird
tissue). This has been achieved by cell culture techni-
ques [19] and intra-cellular detection during the first 10
days of infection [20]. However, the relationship
between viral load (or replication) and virulence has not
been convincingly tested [16]. PCR testing methods
have been developed in order to quantify viral loads
[20-26], which have enabled the viral loads in shed dust
to be directly measured [27,28]. The infectious period is
defined as the total time in which an infected bird sheds
virus [29]. This is determined by the clearance rate and
the lifespan of the individual host. Since there is no
recovery from MDV infection, the infectious period is
defined by a total of four parameters: the disease-
induced mortality, the latent period (the time between
infection and infectiousness of a host) and two other
non-disease associated parameters, namely non-disease
induced mortality and the maximum lifespan of an indi-
vidual (the farm slaughter time in the case of broilers).
Here we present methods for parameter estimation for
MDV isolates, allowing a formal quantification of
infected host lifespan, viral shedding rates and viral
latent periods. The parameters determined from the
analysis allow comparison between isolates of different
virulence in both unvaccinated and vaccinated birds. It
is anticipated that the parameter estimates will be used
for a better understanding of the pathology and aetiol-
ogy of the disease itself and as a platform for investiga-
tion into the causes of virulence evolution.
Results
In the first section, we used survival analysis with a
Weibull mortality function to build a statistical model
for the lifespan of birds infected with MDV. In the sec-
ond section, we developed a dynamic model to simulate
the shedding of virus by a group of birds and used Baye-
sian techniques to estimate the four key infectiousness
parameters: primary and secondary latent periods and
viral shedding rates.
Mortality
An additive covariate Weibull regression model was
fitted to the bird survival data, since the interaction
terms were not significant. The model estimates are
given in Table 1. The Weibull model captures the data
significantly better with the covariates used than without
(p < 0.01). The resulting graphs showing the data and
Weibull model fit are displayed in Figure 1. The model
showed that host lifespan decreased with virulence score
and increased with vaccination (Figure 2 and Table 1),
although there was no significant difference between the
effect of the two vaccines on lifespan (Table 1). On
most days there were either zero or one birds dying
from MDV-related illness from the initial 52 or 53 indi-
vidual birds in each group (Figure 1). These data and
Table 1 Survival analysis: Estimated coefficients of the
covariates in the survival analysis.
Symbol Coefficient Value (95% CI via McMC) zp
r Shape
Parameter
4.18 (3.38,4.99) -11.60 < 0.001
b0 Intercept 4.54 (4.23,4.87) 26.08 < 0.001
b1 Virulence Score -0.53 (-1.01,-0.06) -2.04 0.040
b2 HVT vaccine 0.44 (0.24,0.66) 3.95 < 0.001
b3 Bivalent vaccine 0.35 (0.19,0.52) 4.28 < 0.001
The transformed virulence score is a continuous covariate and the vaccine
treatment is a categorical covariate in an additive regression, giving the test
statistic, z and the corresponding p value. The numbers in brackets are the
95% credible intervals.
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Page 2 of 12further information are published in separate experi-
mental work [30].
Shedding
The dynamic model output records the density of virus
(measured in viral copy number (VCN)/mg dust), which
fitted to the data from each isolator independently. The
model fits can be compared directly in Figures 3, 4 and
5, which give the day of sampling and the sample value.
These data and further information are published in a
separate experimental paper [30].
For each isolator, the median of the posterior distribu-
tion for the four parameters in the model (two latent
periods and two rates of viral shedding) are given in
Tables 2, 3 and 4, where the number of air changes per
hour, a, is set to 15. Assuming a Î [5, 25], the results
obtained in the McMC method did not change, what-
ever value of a is chosen.
A linear model was fitted to account for the variation
in the primary and secondary latent periods, with the
0 10 20 30 40 50 60 70
0
0.2
0.4
0.6
0.8
1
Time (days)
P
r
o
p
o
r
t
i
o
n
 
A
l
i
v
e
(a) Sham, v = 16.5
0 10 20 30 40 50 60 70
0
0.2
0.4
0.6
0.8
1
Time (days)
P
r
o
p
o
r
t
i
o
n
 
A
l
i
v
e
(b) Sham, v =3 6
0 10 20 30 40 50 60 70
0
0.2
0.4
0.6
0.8
1
Time (days)
P
r
o
p
o
r
t
i
o
n
 
A
l
i
v
e
(c) Sham, v =4 6
0 10 20 30 40 50 60 70
0
0.2
0.4
0.6
0.8
1
Time (days)
P
r
o
p
o
r
t
i
o
n
 
A
l
i
v
e
(d) HVT, v = 16.5
0 10 20 30 40 50 60 70
0
0.2
0.4
0.6
0.8
1
Time (days)
P
r
o
p
o
r
t
i
o
n
 
A
l
i
v
e
(e) HVT, v =3 6
0 10 20 30 40 50 60 70
0
0.2
0.4
0.6
0.8
1
Time (days)
P
r
o
p
o
r
t
i
o
n
 
A
l
i
v
e
 
 
(f) HVT, v =4 6
0 10 20 30 40 50 60 70
0
0.2
0.4
0.6
0.8
1
Time (days)
P
r
o
p
o
r
t
i
o
n
 
A
l
i
v
e
(g) Bivalent, v = 16.5
0 10 20 30 40 50 60 70
0
0.2
0.4
0.6
0.8
1
Time (days)
P
r
o
p
o
r
t
i
o
n
 
A
l
i
v
e
(h) Bivalent, v =3 6
0 10 20 30 40 50 60 70
0
0.2
0.4
0.6
0.8
1
Time (days)
P
r
o
p
o
r
t
i
o
n
 
A
l
i
v
e
(i) Bivalent, v =4 6
Figure 1 Mortality: Three different treatments crossed with three different virulence scores as stated. Graphs show data (black),
maximum likelihood estimate of Weibull distribution (red) and 95% credible interval (green). Transformed virulence score (continuous) and
vaccine treatment (categorical) are the (additive) covariates.
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Figure 2 Mortality: Maximum likelihood estimates of l and r
give the mean lifespan(λ (1+1
r), where Γ(z) is the Gamma
function as it varies with virulence score. The dashed lines
represent extrapolation outside virulence scores given in data.
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Page 3 of 12latent period as the response variable and arcsine
square-root transformed virulence score and vaccine
treatment as multiplicative covariates. For the primary
latent period, none of the results were significant (p =
0.41), showing that the primary latent period did not
differ among virus strains and nor was it altered by vac-
cine treatment. For the secondary latent period, neither
virulence score nor HVT vaccine affected the duration
of the latent period, however, Bivalent vaccine increased
the duration of the second latent period significantly
and to a greater extent for smaller virulence scores (see
Table 5).
An association between the virulence score and the
estimated viral shedding rates was found. A linear
regression was used to estimate the viral shedding
rate as a function of arcsine square-root transformed
virulence score and vaccine treatment. There was no
significant association between the primary viral
shedding rate and HVT or Bivalent vaccine treatment
(p = 0.085, 0.10 respectively) nor virulence score
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Figure 3 Viral Shedding: Sham vaccinated treatments. Graphs include the data (black), the maximum likelihood realisation (red) and the 95%
credible interval (green). The panels show each replicate for the virus strains which have been given the virulence score, v as denoted in the
caption.
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Page 4 of 12(p = 0.055). There was, however, a strong positive
association between the virulence score of a strain
and the secondary viral shedding rate (p = 0.00076).
There was no association between the secondary viral
shedding rate and either HVT or Bivalent vaccine
treatment (p = 0.66, 0.39 respectively, see Table 6).
Figure 6 shows the estimated secondary viral shedding
rate as a function of virulence score for different vac-
cine treatments.
Discussion
The survival model fits the nine survival curves well on
the whole, with both replicates combined into one fit.
The delay which characterises the mortality profile for
Marek’s disease is captured well by the Weibull model.
In most cases, the viral shedding model captures the
data well.
The viral shedding model assumes that all birds
become initially infected with MDV. While it is
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Figure 4 Viral Shedding: HVT vaccinated treatments. Graphs include the data (black), the maximum likelihood realisation (red) and the 95%
credible interval (green). The panels show each replicate for the virus strains which have been given the virulence score, v as denoted in the
caption.
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Page 5 of 12difficult to model individual birds based on the resolu-
tion of the data available, we do point out that the
assumption that all birds become infected precipitates
the estimated per bird viral shedding rates being per-
haps an over-estimate of the actual rates. On the other
hand, the qPCR methods used estimate total viral
copies which is not necessarily equivalent to total
infectious material and therefore serves as an upper
limit of viable infectious DNA.
Our estimate of the primary latent period of between
2 and 6 days is much shorter than earlier estimates of
around 13 days [31] but only slightly shorter than more
recent estimates based on new PCR techniques which
have detected significant quantities of virus in feather
tips [32] and feather dander [27,28] at 7 days post
infection. This discrepancy may be due to a number of
factors: detectability of virus at low quantities, the sam-
pling time of the experiments and heterogeneities
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Figure 5 Viral Shedding: Bivalent vaccinated treatments. Graphs include the data (black), the maximum likelihood realisation (red) and the
95% credible interval (green). The panels show each replicate for the virus strains which have been given the virulence score, v as denoted in
the caption.
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Page 6 of 12between the experiments. The estimates here also have
confidence intervals between 0-6 days which suggest the
data are not able to give a great deal of certainty on the
exact time of onset of viral shedding. Further analysis
might take into account biological knowledge through
prior distributions to get a more exact value, and past
experimental studies would suggest shedding begins
towards the end of the estimated interval [27,28].
The pathotyping of MDV isolates, similar to that pio-
neered by Witter and colleagues [1,16], is a useful tool
for comparing the pathogenicity of strains with respect
to others in vaccinated birds. However several of the
more recent isolated, highly virulent strains have ranks
above 80, in some cases 90 on Witter’s ranking system.
Should more virulent strains emerge, it will be difficult
to categorise them via this method, as the scale is trun-
cated at 100. The method of fitting a Weibull distribu-
tion proposed in this paper allows for a greater
flexibility of pathotyping, in that an isolate may be cate-
gorised according to its mean time to kill the host. The
subsequent effect of vaccination of the host on this
metric can then be established.
Biologically, it may seem more sustainable to patho-
type according to the lifespan of an unvaccinated bird,
but experimentally it may also be a solution to the
costly procedure of having two or three groups of birds,
each vaccinated with a different treatment. Even a sim-
ple ‘time to death’ metric can be performed in relatively
few birds, as was the case for the myxoma virus in rab-
bits in Australia. Myxoma strains were pathotyped effec-
t i v e l yw h e nt h ec a s ef a t a l i t yr a t ep r o v e de x p e r i m e n t a l l y
intensive and ineffective in discriminating between simi-
larly virulent strains [33,17] noted this restriction of cur-
rent pathotyping regimes, instead favouring a system
based on neuropathology to circumvent these methodo-
logical and experimental limitations. The analysis pre-
sented here differs from both of these past approaches
due to its epidemiological focus on virulence. However,
we point out that the methodology adopted here only
analyses three distinct strains. Therefore, a wider range
of strain virulences and places of origin will be required
to sufficiently extrapolate the current results to the
whole virulence spectrum.
Conclusions
This paper uses a mathematical approach to estimate
key epidemiological parameters for Marek’s Disease
Virus (MDV). We used survival analysis with a Weibull
mortality function to build a statistical model for the
lifespan of birds infected with MDV. We were able to
Table 2 Viral shedding unvaccinated: median and 95% credible intervals for the posterior distribution of the four
parameters for both replicates of the sham vaccinated factorial study for different virulence scores, v.
VIRULENCE SCORE
PARAMETER 16.5 36 46
Rep 1 Rep 2 Rep 1 Rep 2 Rep 1 Rep 2
1 Latent Period
(days)
6 (2,6) 4 (0,6) 4 (0,6) 4 (0,6) 3 (0,6) 3 (0,6)
2 Latent Period
(days)
10 (7,14) 9 (6,13) 9 (6,13) 9 (6,13) 9 (6,13) 9 (5,13)
1 Shedding Rate
(logVCN/mg dust)
4.87 (3.79,5.25) 3.37 (2.79,4.05) 3.86 (3.30,4.56) 3.28 (2.71,3.95) 3.20 (2.64,3.90) 2.89 (2.34,3.59)
2 Shedding Rate
(logVCN/mg dust)
6.99 (6.72,7.21) 6.89 (6.72,7.07) 7.34 (7.17,7.51) 7.58 (7.41,7.76) 7.69 (7.51,7.85) 7.52 (7.32,7.72)
The numbers in brackets are the 95% credible intervals.
Table 3 Viral shedding HVT vaccination: median and 95% credible intervals for the posterior distribution of the four
parameters for both replicates of the HVT vaccinated factorial study for different virulence scores, v.
VIRULENCE SCORE
PARAMETER 16.5 36 46
Rep 1 Rep 2 Rep 1 Rep 2 Rep 1 Rep 2
1 Latent Period
(days)
5 (0,6) 2 (0,6) 6 (4,6) 6 (2,6) 3 (0,6) 3 (0,6)
2 Latent Period
(days)
12 (8,17) 10 (7,13) 11 (8,14) 12 (8,16) 10 (6,13) 9 (6,13)
1 Shedding Rate
(logVCN/mg dust)
3.79 (3.34,4.20) 2.44 (1.93,3.02) 4.58 (4.19,4.92) 4.56 (4.13,4.91) 2.70 (2.16,3.42) 4.15 (3.58,4.82)
2 Shedding Rate
(logVCN/mg dust)
6.83 (6.61,7.04) 6.35 (6.18,6.52) 7.49 (7.28,7.70) 7.53 (7.31,7.75) 7.50 (7.32,7.67) 7.29 (7.11,7.46)
The numbers in brackets are the 95% credible intervals.
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cine covariates by calculating credible intervals via Baye-
sian methods. We developed a dynamic model to
simulate the shedding of virus by a group of birds and
used Bayesian techniques to estimate the four key infec-
tiousness parameters: primary and secondary latent peri-
ods and viral shedding rates.
We applied these methods to the data for three MDV
strains varying moderately in virulence. From the survi-
val analysis, we found that increasing the virulence score
of a virus strain decreases the lifespan of the host (Fig-
ure 2). Vaccinating the host with either the first or sec-
ond generation vaccine increases its lifespan, but neither
one to any greater degree (Table 1). From the viral
shedding analysis, we concluded primary latent period is
not affected by vaccination or virulence score, however,
secondary latent period increases with Bivalent vaccine
treatment (Table 5). Secondary (long term) viral shed-
ding rate (measured in VCN per mg dust) is higher for
strains of higher virulence (Table 5 and Figure 6). Vacci-
nation does not reduce long term viral shedding rate
significantly. Together, these results imply that more
virulent viruses shed more infectious material into the
environment and Bivalent vaccines reduce the infectious
period, especially for less virulent strain infections.
The results described here are qualitatively in line
with current thinking on MDV pathogenesis, but the
new methods presented allow a formal comparison of
strains in an epidemiological meaningful way. It is
anticipated that this analysis will allow a more quantita-
tive understanding of the aetiology of MDV and the
mechanisms governing a functional rise in virulence for
a strain. With this analysis it is hoped that a more epi-
demiologically significant classification of MDV strains
will emerge which will eventually provide not only
insight into the reasons for evolution to highly virulent
strains but also a metric to evaluate future risks and the
efficacy of possible control strategies.
Methods
Experimental Data
We look at a single experiment [30] with two response
variables measured. Groups of maternal antibody posi-
tive IsaBrown layer chicks were inoculated with one of
three vaccine treatments: sham (diluent only), HVT
(first generation industry vaccine) or Bivalent (second
generation industry vaccine) at one day old. At 5 days
post vaccination, the birds were challenged with 500 pfu
(plaque forming units) of one of three MDV strains:
04CRE, MPF57 and 02LAR. These independently
s a m p l e di s o l a t e sw e r eA u s t r a l i a ni no r i g i na n dh a v e
been pathotyped with virulence scores (the percentage
of HVT or Bivalent vaccinated chickens infected with a
Table 4 Viral shedding bivalent vaccination: median and 95% credible intervals for the posterior distribution of the
four parameters for both replicates of the Bivalent vaccinated factorial study for different virulence scores, v.
VIRULENCE SCORE
PARAMETER 16.5 36 46
Rep 1 Rep 2 Rep 1 Rep 2 Rep 1 Rep 2
1 Latent Period
(days)
4 (0,6) 2 (0,5) 3 (0,6) 3 (0,6) 3 (0,6) 3 (0,6)
2 Latent Period
(days)
14 (9,19) 23 (18,27) 15 (10,19) 9 (6,13) 10 (6,13) 10 (6,13)
1 Shedding Rate
(logVCN/mg dust)
4.87 (3.27,5.19) 3.37 (3.27,3.83) 3.86 (2.92,4.70) 3.28 (2.93,4.14) 3.20 (2.94,4.18) 2.89 (2.49,4.69)
2 Shedding Rate
(logVCN/mg dust)
6.23 (6.02,6.45) 5.85 (5.61,6.09) 7.16 (6.94,7.37) 6.95 (6.78,7.13) 6.96 (6.78,7.12) 7.28 (7.11,7.45)
The numbers in brackets are the 95% credible intervals.
Table 5 Secondary latent period: linear regression results
for effect of transformed virulence score and vaccine
treatment on the secondary latent period (days).
Estimate Std. Error t value Pr(> |t|)
Intercept 10.16 4.30 2.36 0.04
Virulence Score -1.64 6.98 -0.24 0:82
VaccHVT 2.60 6.10 0.43 0:68
VaccBiv 19.29 6.10 3.16 < 0.01
Virulence Score:VaccBiv -24.82 9.88 -2.51 0.03
Virulence Score:VaccHVT -1.82 9.88 -0.18 0.86
Adjusted R
2 = 0.54, p = 0.01.
Table 6 Secondary viral shedding: linear regression
results for effect of transformed virulence score and
vaccine treatment on the second viral shedding rate
(VCN/mg dust).
Estimate Std. Error t value Pr(> |t|)
Intercept -3.24 × 10
7 1.35 × 10
7 -0.24 0.03
Virulence Score 9.79 × 10
7 2.19 × 10
7 4.47 < 0.01
VaccHVT 8.51 × 10
6 1.91 × 10
7 0.45 0.66
VaccBiv 1.70 × 10
7 1.91 × 10
7 0.89 0.39
Virulence Score:VaccBiv -5.73 × 10
7 3.19 × 10
7 -0.19 0.09
Virulence Score:VaccHVT -2.37 × 10
7 3.10 × 10
7 -0.77 0.46
Adjusted R
2 = 0.74, p < 0.01.
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Page 8 of 12particular strain which develop gross lesions or die of
MDV within eight weeks [34]) of 16.5, 36 and 46 respec-
tively. The viruses were all isolated from field outbreaks
and used at passage level 4 to 7 in chick kidney cells. The
experiment was therefore a 3 × 3 factorial design study,
with vaccine type fully cross-factored against virus strain.
Each treatment combination was replicated in two sepa-
rate isolators resulting in 26 or 27 birds per combination
for the pathotyping component of the study. The air in
each isolator was changed 8-20 times per hour. Further
details can be found in [30]. The experiment was
approved by the University of New England Animal
Ethics Committee with approval number AEC05/076.
Due to Animal Ethics regulations, birds thought to be
nearing death were euthanised and classified as mortality
in the experimental results. The experiment lasted 56
days post infection (dpi) and all birds were humanely
killed and examined for MD lesions on the last day.
Therefore for the purposes of this analysis, the data were
censored after day 55. All birds were given a large dose of
MDV (500 pfu) via intra-abdominal injection and it was
therefore assumed that all the birds were infected and
would shed the virus. Differences between unvaccinated
and vaccinated birds in detection of MD have been
reported [35], but these have been in studies where infec-
tion has been by injection with 50 pfu. Increasing the
MDV dose fourfold (from 50 to 200 pfu) significantly
increased the detected incidence of MD in unvaccinated
birds from 64% to 81% [27].
The two variables recorded were the time to death of
a bird (measured in days) and the density of virus within
each isolator every week (measured in logVCN per mg
of dust in the environment). The virus titres in the dust
were determined via quantitative real-time PCR of dust
collected from the isolator exhaust ducts, the methods
of which have been discussed in separate studies [25].
The data are shown in Figures 1 (mortality), 3, 4 and 5
(shedding).
Parameter Estimates
W ea s s u m e dt h a te a c hi n f e c t e db i r ds t a r t ss h e d d i n g
virus after an initial delay, then after a further delay, the
rate at which it sheds virus rises to a long-term stable
value. We estimated five key epidemiological para-
meters: host lifespan, primary latent period (the time
until an infected bird becomes infectious), secondary
latent period (the delay between an infectious bird first
shedding virus and when it sheds virus at its secondary
long term rate) and viral shedding rates (both primary
and secondary, measured in VCN/mg dust). A survival
analysis was undertaken for the mortality data because
multiple covariates were needed to find the host life-
span. These covariates were vaccine treatment and virus
virulence score. Latent period and rate of viral shedding
could not be estimated directly from the data since the
response variable (measured weekly in VCN per mg
dust) could vary with the number of birds housed
together, which changed as birds died. Therefore a
dynamic model capturing this variability was used to
estimate the two infectiousness parameters.
For ease of notation, log is written to represent log10
throughout the paper.
Mortality
The biology of Marek’s disease suggests that the prob-
ability of death by MDV infection changes through time,
since the virus undergoes lytic, latent stage (this is a
description of an MDV pathogenesis stage and not
equivalent to the ‘latent periods’ in the epidemiological
context which this study estimated), late lytic (where
infection is extended to other organs of the host), and
transformative (tumour-induction) stages. These stages
are pathologically distinct and may lead to a different
mortality rate. Therefore, a Weibull distribution was cho-
sen as a candidate distribution for modelling survivorship
curves, which is often used for time to death data since it
is flexible and can mimic other distributions but only has
two parameters in its non-location form. We therefore
assumed that time to death can be modelled as a random
variable, T, such that T ~ W(r, l)w h e r er, l >0a r et h e
shape and scale parameters respectively. The associated
probability density function is
f(t)=

r
λ( t
λ)
r−1
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Figure 6 Viral Shedding: Linear regression analysis of the
virulence score and the corresponding estimated secondary
viral shedding rate for all treatments. The 95% confidence
intervals for the mean response are given in fainter lines. The linear
regression results are shown in Table 6.
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Page 9 of 12A Weibull model was fitted to the survival data in the
study. In the case when r = 1, the distribution collapses
to an exponential distribution. When r >1o rr <1
there is an increasing or decreasing chance of death
over time respectively. Coefficients, b, are such that l =
exp(b · x), where b =[ b0, b1, b2, b3] are the covariate
coefficients and x =[ 1 ,x1, x2, x3]
T are the covariates. In
this analysis, there were three covariates (one continu-
ous: the transformation of the virulence score of an iso-
late (x1) and two binary: the presence or absence of
HVT (x2) and Bivalent (x3) vaccine). Therefore there
were 9 combinations on the set of possible covariates,
thus lj = b·xj where j Î [1, 9] The likelihood function
can therefore be written
L(λ,r)=
9 
j=1
n 
i=i

r
λj

ti
λj
r−1δi
exp

−
ti
λj
r
where δi is zero when the ith observation is censored
and unity elsewhere. This function was maximized via
the Newton-Raphson algorithm such that
L(˜ λ,˜ r) =m a xL(λ,r) where ˜ λ and ˜ r are the maximum
likelihood estimates. Note that the virulence score, v,o f
an isolate is a percentage measure and to be used as an
explanatory variable in a regression analysis, it should
be transformed such that vT = arcsin
√
0.01v.T h e
regression fitted the maximum likelihood estimates for
b, however further Bayesian analysis was required to
estimate the associated credible intervals when the cov-
ariate covariance matrix does not approximate the iden-
tity matrix. An McMC framework was set up in
WinBUGS [36] to calculate the posterior distributions
and the credible intervals of the Weibull survival
function.
The prior distributions of each parameter were
assumed to be uninformative and were thus taken as
uniform, to ensure equivalence to maximum likelihood
estimation. The burn-in was set to 22,000 iterations
with every 10th sample taken from the subsequent
100,000 iterations [37,38].
Viral Shedding
The dynamic model tracked the density of MDV over
time in each isolator. In this model it is assumed:
1) After MDV infection, there is a delay before virus is
first shed [31]. This is termed the primary latent period.
2) After this primary latent period, virus is shed at a
constant rate (the primary viral shedding rate, measured
in VCN per mg dust) for a set period of time, termed
the secondary latent period.
3) Once this secondary latent period is over, virus is
shed at a constant rate (the secondary viral shedding
rate) until the termination of the experiment.
Additionally, the density of virus (VCN per mg dust)
was calculated at the end of each day and any removal
of birds was assumed to occur at the start of the day.
While all parameters are assumed to be constant across
all the birds in a single isolator, they can vary between
isolators.
There are therefore four parameters estimated per
isolator: the primary/secondary latent periods (in days)
and the primary/secondary rates of viral shedding
(VCN/mg dust). The primary and secondary latent peri-
ods are denoted by T
1 and T
2 respectively. Birds shed
virus at a rate, a
1 (VCN per mg dust) from T
1+1 to T
1
+T
2 days post infection; and at a rate a
2 (VCN per mg
dust) from T
2+1 until the end of the experiment (at 8
weeks post infection). The density of MDV in the
dynamic model could be compared to the amount of
virus recorded in the data (sampled every 7 days). We
therefore estimated a1
j (v), a2
j (v), T1
j (v) and T2
j (v) for each
virulence score v Î {16.5, 36, 46} and each vaccine
status j Î {Sham, HVT, Bivalent}.
The model accounts for the removal of birds given in
the mortality data and the number of complete hourly
air changes (varied as a parameter a). The daily quantity
of dust shed per bird was calculated by fit ting a cubic
spline to dust MDV data provided from the same
experiment [30].
To calculate the measurement error of a quantity of
virus in a sample of dust we noted that a final MDV
d e n s i t yw a sr e a c h e ds o m et i m eb e f o r et h ee n do ft h e
sampling period. Such data can therefore be assumed to
be identically and independently distributed. If Y1 and
Y2 are samples from the experiment when the virus den-
sity and the data are lognormally distributed then:
logY1,logY2 ∼ N(μ,σ2)
⇒ logY1 − logY2 ∼ N(0,2σ2)
To find the time point after which the data is assumed
to have plateaued, four sets of points were examined:
weeks 5, 6, 7 and 8. The differences between the logged
data of weeks 7-8 provided the highest probability of
both being drawn from a normal distribution (p =0 . 8 ,
Anderson-Darling n = 18) and that the distribution has
a mean of zero (p = 0.40). The resulting standard devia-
tion of the difference between log-transformed data was
estimated to be 0.33 logVCN/mg dust.
Posterior distributions were found by means of McMC
realisations by calculating the likelihood of the data
given the parameter values, with lognormal errors of s
2
= 0.33
2/2. The burn-in time was set to 30,000 iterations
and the posterior distribution was taken as every 10th
sample from the following 90,000 iterations [37,38].
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